Core Viewpoint - The company reported a decline in both revenue and net profit for the third quarter and the first three quarters of the year, indicating potential challenges in its financial performance [1] Financial Performance Summary - The company's revenue for the third quarter was 300 million, a year-on-year decrease of 10.99% [1] - The net profit for the third quarter was 72.51 million, reflecting a year-on-year decline of 27.02% [1] - For the first three quarters, the total revenue was 936 million, showing a slight year-on-year decrease of 0.20% [1] - The net profit for the first three quarters was 234 million, which represents a year-on-year decline of 3.07% [1]

花园生物公告，第三季度营收为3亿元，同比下降10.99%；净利润为7251.23万元，同比下降27.02%。前 三季度营收为9.36亿元，同比下降0.20%；净利润为2.34亿元，同比下降3.07%。 ...

Core Viewpoint - Garden Biologics (300401.SZ) reported a slight decline in revenue and net profit for the first three quarters of the year, while showing growth in net profit excluding non-recurring items [1] Financial Performance - The company's operating revenue for the first three quarters reached 936 million yuan, representing a year-on-year decrease of 0.20% [1] - The net profit attributable to shareholders was 234 million yuan, down 3.07% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 221 million yuan, reflecting a year-on-year increase of 9.06% [1]

浙江花园生物医药股份有限公司 2025 年第三季度报告 | | | 浙江花园生物医药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 浙江花园生物医药股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 300,340,615.92 | -10.99% | 935,701,786.71 | -0.20% | | ...

（文章来源：证券日报） 证券日报网讯花园生物10月15日在互动平台回答投资者提问时表示，截至2025年10月10日，公司股东总 户数为28，597户。 ...

证券日报网讯 花园生物10月10日在互动平台回答投资者提问时表示，公司2025年第三季度报告预约披 露日为2025年10月18日，具体业绩情况可关注公司届时披露的定期报告。花园药业目前主要专注于心血 管、神经系统等慢性疾病领域仿制药的研发、生产和销售，暂未涉及创新药。 （编辑 袁冠琳） ...

Core Viewpoint - Garden Bio is focused on the development, production, and sales of generic drugs for chronic diseases, particularly in the cardiovascular and nervous system sectors, and has not yet ventured into innovative drugs [1] Company Overview - Garden Bio was established in December 2000 and was listed on the Shenzhen Stock Exchange's ChiNext board on October 9, 2014 [1] - The company has developed a complete industrial chain for Vitamin D3 over more than two decades [1] - Garden Bio's four main product categories—refined lanolin, lanosterol, Vitamin D3, and 25-hydroxy Vitamin D3—are among the global leaders in production capacity [1] Financial Performance - In the first half of 2025, Garden Bio reported revenue of approximately 635 million yuan, representing a year-on-year increase of 5.86% [1] - The net profit attributable to the parent company was approximately 162 million yuan, reflecting a year-on-year increase of 13.67% [1] Future Disclosure - The company has scheduled the disclosure date for its Q3 2025 report on October 18, 2025, and investors are encouraged to monitor the regular report for specific performance details [1]

浙江花园生物医药股份有限公司 关于 2025 年第三季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、"花园转债"（债券代码：123178）转股期限为2023年9月11日至2029年3月5日； 最新的转股价格为人民币13.45元/股。 2、2025年第三季度，共有278张"花园转债"完成转股（票面金额共计人民币 27,800.00元），合计转成2,065股"花园生物"股票（证券代码：300401）。 3、截至2025年第三季度末，"花园转债"剩余债券张数为11,759,903张，剩余票 面总额为人民币1,175,990,300.00元。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，浙江花园生物医药股份有限公司（以 下简称"公司"）现将2025年第三季度可转换公司债券（以下简称"可转债"）转股及 公司股份变化情况公告如下： | 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-042 | | --- | --- | ...

Group 1 - The company Garden Biologics announced the complete sale of 7,674,790 shares held under its 2022 employee stock ownership plan, representing 1.41% of the total share capital [2] - The sale was conducted in compliance with market trading rules and regulations set by the China Securities Regulatory Commission and Shenzhen Stock Exchange, ensuring no insider trading occurred [2] - Following the sale, the company will proceed with the asset settlement and distribution related to the employee stock ownership plan and will terminate the plan as per regulations [2]

Core Viewpoint - Garden Biologics (300401.SZ) has completed the sale of 7,674,790 shares held under its 2022 employee stock ownership plan, representing 1.41% of the company's total share capital [1] Summary by Sections - **Share Sale Details** - The company sold all shares through centralized bidding [1] - The total shares sold accounted for 1.41% of the current total share capital [1] - **Compliance and Regulations** - During the sale period, the company strictly adhered to market trading rules [1] - The company complied with the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding trading during sensitive information periods [1] - There were no instances of insider trading during the sale [1]